Malignant Liver TumorHEALNCT06870461
Hepatic Excision and Ablation Log
An observational study of Malignant Liver Tumor and Benign Liver Tumor, run by University Hospital, Antwerp.
Trial summary
This study aims to establish a registry for liver surgery and ablation procedures to improve patient care, advance research, and enhance surgical quality. The registry will collect pseudonymized data on patient demographics, disease characteristics, procedural details, and outcomes. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Malignant Liver Tumor, Benign Liver Tumor
- What is being tested?
- Liver surgery / ablation
- Type of treatment
- Surgery or procedure
- How many people
- 1,000 participants
- Where
- No sites listed yet
- Study dates
- 1 Apr 2025to Jan 2040
- How long will I take part?
- 10 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: All patients who will undergo liver surgery or ablation.
Who may be able to join
- Both benign and malignant liver lesions are included
Who cannot join
- Intervention performed solely for liver biopsy, without any subsequent surgical resection or ablation.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
This study aims to establish a registry for liver surgery and ablation procedures to improve patient care, advance research, and enhance surgical quality. The registry will collect pseudonymized data on patient demographics, disease characteristics, procedural details, and outcomes.
Read the detailed description
The purpose of this registry is to create a comprehensive list of individuals who have undergone liver surgery or liver ablation, allowing researchers and clinicians to assess their data in future studies if they meet the eligibility criteria. All patients who have received liver surgery or liver ablation procedures at our institution will be included in this registry.
Information collected as part of the registry will be used solely to assess potential participants' eligibility for research studies, allowing for the evaluation of long-term outcomes, identification of risk factors, and investigation of therapeutic interventions. This data will help to enhance the understanding of the patient population undergoing liver surgery and improve clinical practices.
A patient registry is an organized system that uses observational study methods to collect standardized clinical data and other relevant information. It aims to evaluate specific outcomes for individuals who have undergone liver surgery or ablation, serving scientific, clinical, and policy-related purposes. The registry will support the development of targeted research studies and provide valuable insights into the treatment and management of liver diseases.
- Conditions
- Malignant Liver Tumor, Benign Liver Tumor
- Being tested
- Liver surgery / ablation
- Medical subject headings
- Carcinoma, Hepatocellular
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Liver surgery / ablationProcedure or surgery
Any type of liversurgery or CT-guidede liver ablation
What is being measured
The primary outcome is the main question the study is designed to answer.
Establishment of a Liver Surgery and Ablation Registry
The primary objective of this study is to create a comprehensive registry of patients who have undergone liver surgery or liver ablation. This registry will serve as a foundation for future epidemiological studies, enabling the assessment of long-term outcomes, the identification of risk factors, and the evaluation of potential therapeutic interventions. Data collected will include demographic information, medical history, surgical details, postoperative outcomes, and survival rates. By compiling this data, we aim to better understand the patient population and improve care for individuals undergoing liver surgery or ablation.
Measured: 10 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Mar 2025
- Study start1 Apr 2025 (estimated)
- Primary completionJan 2035 (estimated)
- Study completionJan 2040 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Malignant Liver TumorStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 1,000 participants (estimated)
- Target duration
- 10 Years
Sponsor and investigators
- Lead sponsor
- University Hospital, Antwerp
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Thiery Chapelle, Principal investigator, University Hospital, Antwerp
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06870461
- Sponsor's protocol ID
- 003810
- Acronym
- HEAL
- Status last verified
- Mar 2024
- First submitted
- 18 Dec 2024
- Last updated
- 11 Mar 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 Mar 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Hepatic Excision and Ablation Log
- ClinicalTrials.gov ID
- NCT06870461
- Acronym / sponsor ID
- HEAL / 003810
- Conditions
- Malignant Liver Tumor, Benign Liver Tumor
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 1,000 participants (estimated)
- Lead sponsor
- University Hospital, AntwerpUniversity, hospital or other
- Study start
- 1 Apr 2025 (estimated)
- Primary completion
- Jan 2035 (estimated)
- Study completion
- Jan 2040 (estimated)
- First posted
- 11 Mar 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to establish a registry for liver surgery and ablation procedures to improve patient care, advance research, and enhance surgical quality. The registry will collect pseudonymized data on patient demographics, disease characteristics, procedural details, and outcomes.
Detailed description
The purpose of this registry is to create a comprehensive list of individuals who have undergone liver surgery or liver ablation, allowing researchers and clinicians to assess their data in future studies if they meet the eligibility criteria. All patients who have received liver surgery or liver ablation procedures at our institution will be included in this registry.
Information collected as part of the registry will be used solely to assess potential participants' eligibility for research studies, allowing for the evaluation of long-term outcomes, identification of risk factors, and investigation of therapeutic interventions. This data will help to enhance the understanding of the patient population undergoing liver surgery and improve clinical practices.
A patient registry is an organized system that uses observational study methods to collect standardized clinical data and other relevant information. It aims to evaluate specific outcomes for individuals who have undergone liver surgery or ablation, serving scientific, clinical, and policy-related purposes. The registry will support the development of targeted research studies and provide valuable insights into the treatment and management of liver diseases.
Study design
- Observational model
- Other
- Time perspective
- Prospective
- Target follow-up
- 10 Years
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- All patients who will undergo liver surgery or ablation.
Key inclusion criteria (1 listed)
- Both benign and malignant liver lesions are included
Key exclusion criteria (1 listed)
- Intervention performed solely for liver biopsy, without any subsequent surgical resection or ablation.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Liver surgery / ablationAny type of liversurgery or CT-guidede liver ablation | Procedure or surgery | – |
Primary outcome
Establishment of a Liver Surgery and Ablation Registry
Time frame: 10 years
The primary objective of this study is to create a comprehensive registry of patients who have undergone liver surgery or liver ablation. This registry will serve as a foundation for future epidemiological studies, enabling the assessment of long-term outcomes, the identification of risk factors, and the evaluation of potential therapeutic interventions. Data collected will include demographic information, medical history, surgical details, postoperative outcomes, and survival rates. By compiling this data, we aim to better understand the patient population and improve care for individuals undergoing liver surgery or ablation.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Mar 2025.
- Individual participant dataSharing planned: No
Related trials for Malignant Liver Tumor
Active, not recruitingPhase 2
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Active, not recruitingPhase 1
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Anal Carcinoma, Bladder Carcinoma
RecruitingPhase 2
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc)
Recruiting
Simultaneous vs. Staged Resection of Colorectal Cancer With Synchronous Liver Metastases
Colorectal Cancer, Colorectal Neoplasms Malignant
Active, not recruitingPhase 2
Software-Aided Imaging (Morfeus) for Confirming Tumor Coverage With Ablation in Patients With Liver Tumors, the COVER-ALL Study
Malignant Liver Neoplasm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Thiery Chapelle principal investigator
University Hospital, Antwerp
Questions about this trial
What is this clinical trial studying?
An observational study of Malignant Liver Tumor and Benign Liver Tumor, run by University Hospital, Antwerp.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 11 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Bart Hendrikx (+3238214327, hepatobiliaireheelkunde@uza.be), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Establishment of a Liver Surgery and Ablation Registry (time frame: 10 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Mar 2025.